SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 11/21/2016 5:41:06 PM - Followers: 189 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RNN News: Current Report Filing (8-k) 11/25/2016 04:04:05 PM
RNN News: Quarterly Report (10-q) 11/04/2016 04:18:21 PM
RNN News: Current Report Filing (8-k) 09/20/2016 04:59:50 PM
RNN News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/15/2016 05:11:24 PM
RNN News: Current Report Filing (8-k) 09/14/2016 09:08:53 AM
PostSubject
#3117   No it's on the NYSE capital market. It Valensio 11/21/16 05:41:05 PM
#3116   Anyone know? mno987 11/20/16 08:30:56 PM
#3115   I wouldn't call a nickel rise a pop. Valensio 11/19/16 08:33:11 PM
#3114   $RNN Daily & Weekly Chart http://stockcharts. $Pistol Pete$ 11/18/16 12:32:20 PM
#3113   Is RNN in danger of losing it's listing? mno987 11/18/16 10:51:57 AM
#3112   Y the heavy volume n big pop in ttubular 11/17/16 01:33:53 PM
#3111   RNN 0,19 + 8.10% harmsen 11/17/16 12:26:51 PM
#3110   3 day confirmation, so the seatbelt is strapped slmlrd 11/13/16 10:14:59 PM
#3109   RNN looks to finally break out. Bottom was chickpea598 11/11/16 12:06:09 PM
#3108   Earnings soon. What's gonna get this pig to move. slmlrd 11/03/16 11:51:15 AM
#3107   No doubt! Old ir out. slmlrd 11/02/16 06:50:12 PM
#3106   This appears dead until sometime in 2017. This Valensio 11/02/16 06:01:35 PM
#3105   RNN got approvals, unfortunately the news gave the slmlrd 10/30/16 01:28:27 AM
#3104   finance.yahoo.com/news/rexahn-pharmaceuticals-receives-u-patent-130000658.h Theo 10/26/16 09:10:09 AM
#3103   Actually support and hammer pattern may be a slmlrd 10/17/16 05:19:24 PM
#3102   That is true. So it'll likely rise beginning Valensio 10/17/16 12:05:31 PM
#3101   November tax selling will also contribute to downward slmlrd 10/17/16 12:04:21 PM
#3100   Ouch! slmlrd 10/14/16 01:24:38 AM
#3099   .04 target! slmlrd 10/13/16 05:43:54 PM
#3098   It's a garbage company Shane Chowdhury 10/13/16 11:54:50 AM
#3097   Any news to just dump shares onto investors. slmlrd 10/12/16 08:50:30 PM
#3096   Dilution not good! slmlrd 10/12/16 06:40:58 PM
#3095   The recent news & seeking alpha article did Valensio 10/12/16 01:12:13 PM
#3094   News came out after market closed will spike eco56 10/11/16 10:21:42 PM
#3093   News came out after market closed will spike eco56 10/11/16 10:21:37 PM
#3092   News came out after market closed will spike eco56 10/11/16 10:21:23 PM
#3091   News came out after market closed will spike eco56 10/11/16 10:21:21 PM
#3090   I'm not in and haven't been for some Theo 10/09/16 09:57:16 PM
#3089   Nothing's moving rnn. slmlrd 10/09/16 05:13:35 PM
#3088   finance.yahoo.com/news/rexahn-pharmaceuticals-presents-preliminary-efficacy Theo 10/04/16 09:24:40 AM
#3087   See what happens in the low teens. slmlrd 09/30/16 10:57:17 AM
#3086   Nope not until people start dumping portfolio slmlrd 09/28/16 06:19:44 PM
#3085   I think we have reversal from that point. Shane Chowdhury 09/27/16 09:49:11 PM
#3084   Nice volume today harmsen 09/27/16 01:02:44 PM
#3083   I guess someone who has better info then ttubular 09/14/16 04:26:57 PM
#3082   I wonder who are these institutional investors who Valensio 09/14/16 01:15:19 PM
#3081   finance.yahoo.com/news/rexahn-announces-6-million-registered-130000763.html Theo 09/14/16 09:35:32 AM
#3080   Like you still waiting..... pineyhill 08/15/16 12:25:02 PM
#3079   So dead on this board, you can hear TheSaint09 08/12/16 11:13:43 AM
#3078   http://www.conferencecalltranscripts.org/Q/summary2/?id=2977576 Valensio 08/05/16 04:44:37 PM
#3077   New hire at rexahn http://finance.yahoo.com/news/rexahn-pharmaceuticals-strength Valensio 07/11/16 11:46:49 AM
#3076   RNN really loves the mid .20's, can anything Valensio 07/05/16 01:14:47 PM
#3075   green today. good things to come!!! BioMania 06/29/16 06:08:25 PM
#3074   what joke im out glta CashMoneyNY 06/27/16 09:58:47 AM
#3073   CAN WE GET A PARTY GOING ON HERE?????????????? BioMania 06/23/16 04:48:34 PM
#3072   flippers killing us here jeez just sell already CashMoneyNY 06/23/16 10:58:39 AM
#3071   HOLD !! ITS GONNA RUN HUGE BIDS AND SLAPS CashMoneyNY 06/22/16 12:19:34 PM
#3070   Ask Is Thin to .31+ glta CashMoneyNY 06/22/16 11:45:35 AM
#3069   Once the flippers get out it will fly CashMoneyNY 06/22/16 11:42:57 AM
#3068   End of day will be interesting glta CashMoneyNY 06/22/16 11:42:15 AM
PostSubject